MEI Pharma Inc. | Mutual Funds
Mutual Funds that own MEI Pharma Inc.
Vanguard Total Stock Market Index Fund
896,606
1.26%
15,800
0%
07/31/2018
Vanguard Extended Market Index Fund
388,861
0.55%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
156,034
0.22%
0
0%
07/31/2018
iShares Micro Cap ETF
95,438
0.13%
0
0.04%
09/06/2018
Acuitas US Micro Cap Fund
86,300
0.12%
1,100
0.33%
09/30/2017
DFA US Core Equity 2 Portfolio
83,632
0.12%
4,393
0%
04/30/2018
Russell US Small Cap Equity Fund
77,115
0.11%
-7,235
0.02%
04/30/2018
DFA US Targeted Value Portfolio
72,586
0.1%
0
0%
04/30/2018
Fidelity Spartan Total Market Index Fund
62,189
0.09%
0
0%
07/31/2018
Vanguard Institutional Total Stock Market Index Fund
61,287
0.09%
0
0%
07/31/2018
| Address |
3611 Valley Centre Drive
San Diego California 92130
United States
|
|
Employees
|
- |
| Website |
http://www.meipharma.com |
| Updated |
07/08/2019 |
| MEI Pharma, Inc. engages in the clinical development of novel therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, a highly selective, oral PI3K delta inhibitor; voruciclib, an oral, selective CDK inhibitor; and ME-344, a novel mitochondrial inhibitor. |
